Pharmaceuticals - Indian - Formulations
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2018 | FY 2017 |
---|---|---|---|---|---|
Total Revenue | 560.24 | 422.81 | 421.26 | 279.98 | 278.13 |
Total Expenses | 543.78 | 457.35 | 441.60 | 305.20 | 641.05 |
Profit Before Tax | 16.46 | 26.04 | -19.60 | -53.38 | -362.91 |
Profit After Tax | 14.23 | 26.04 | -20.02 | -54.13 | -363.81 |
Operating Profit after Depreciation | 79.40 | 25.22 | 36.82 | -18.17 | -346.60 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2018 | FY 2017 |
---|---|---|---|---|---|
Fixed Assets | 184.05 | 216.46 | 235.50 | 310.68 | 342.31 |
Total Non Current Assets | 312.68 | 375.83 | 389.31 | 428.64 | 391.91 |
Total Current Assets | 341.79 | 273.38 | 242.44 | 186.11 | 267.84 |
TOTAL ASSETS | 654.47 | 649.21 | 631.76 | 614.75 | 659.75 |
Total Shareholder's Fund | -690.83 | -704.70 | -720.32 | -663.18 | -619.86 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2018 | FY 2017 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 15.28 | 73.05 | 50.20 | 7.17 | -1.72 |
Net Cash used in Investing Activities | 76.61 | -29.35 | -18.42 | -6.42 | 4.14 |
Net Cash used in Financing Activities | -42.08 | -46.56 | -44.60 | -6.17 | -10.71 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 560.24 | 422.81 | 421.26 | 371.28 | 345.40 |
Total Expenses | 543.78 | 457.35 | 441.60 | 399.57 | 368.46 |
Profit Before Tax | 16.46 | 26.04 | -19.60 | -29.49 | -16.66 |
Profit After Tax | 14.23 | 26.04 | -20.02 | -29.82 | -19.12 |
Operating Profit after Depreciation | 79.40 | 25.22 | 36.82 | 23.89 | 5.62 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 184.05 | 216.46 | 235.50 | 244.01 | 269.66 |
Total Non Current Assets | 312.68 | 375.83 | 389.31 | 406.40 | 373 |
Total Current Assets | 341.79 | 273.38 | 242.44 | 265.17 | 228.65 |
TOTAL ASSETS | 654.47 | 649.21 | 631.76 | 671.57 | 601.65 |
Total Shareholder's Fund | -690.83 | -704.70 | -720.32 | -695.16 | -713.12 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 15.28 | 73.05 | 50.20 | 83.19 | 34.60 |
Net Cash used in Investing Activities | 76.61 | -29.35 | -18.42 | -16.71 | -11.35 |
Net Cash used in Financing Activities | -42.08 | -46.56 | -44.60 | -54.25 | -26.20 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 136.35 | 113.85 | 135.23 | 102.56 | 115.92 |
Total Expenses | 121.94 | 110.63 | 120.74 | 98.07 | 104.78 |
Profit Before Tax | 4.12 | 28.24 | 39.77 | -14.97 | -10.70 |
Profit After Tax | 4.11 | 28.24 | 37.54 | -14.97 | -10.71 |
Operating Profit after Depreciation | 19.04 | 43.15 | 61.08 | 7.11 | 14.29 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 136.35 | 113.85 | 135.23 | 102.56 | 115.92 |
Total Expenses | 121.94 | 110.63 | 120.74 | 98.07 | 104.78 |
Profit Before Tax | 4.12 | 28.24 | 39.77 | -14.97 | -10.70 |
Profit After Tax | 4.11 | 28.24 | 37.54 | -14.97 | -10.71 |
Operating Profit after Depreciation | 19.04 | 43.15 | 61.08 | 7.11 | 14.29 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Ind-Swift Ltd | ₹18.19 | ₹98.53 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
21 Jan 2025, 02:05 pm
08 Nov 2024, 04:42 pm
03 Sep 2024, 05:11 pm
03 Sep 2024, 11:40 am
02 Aug 2024, 05:33 pm